<DOC>
	<DOC>NCT01947777</DOC>
	<brief_summary>To evaluate the effect of rifampin, a cytochrome P450 3A (CYP3A) inducer, on the pharmacokinetics (PK) of IPI-145; to assess the safety and tolerability of IPI-145 when administered with rifampin in healthy subjects</brief_summary>
	<brief_title>Phase 1 Study in Healthy Subjects to Evaluate the Effect of Rifampin on the Pharmacokinetics of IPI-145</brief_title>
	<detailed_description>- In Treatment Period 1, subjects will receive a single 25 mg oral dose of IPI-145 - In Treatment Period 2, on Days 3-9, the same subjects will receive once daily (QD) oral doses of 600 mg rifampin; on Day 9, subjects will receive a single oral dose of 25 mg IPI-145 concomitantly administered with 600 mg of rifampin</detailed_description>
	<mesh_term>Rifampin</mesh_term>
	<criteria>Healthy men or women of nonchildbearing potential between 1850 years of age Body Mass Index (BMI): 18.0 32.0 kg/m2 In good health, determined by no clinically significant findings from clinical evaluations Provided written informed consent prior to any study specific procedures Women of childbearing potential Evidence of clinically significant medical conditions History of gastrointestinal disease or surgery that may affect drug absorption Positive or indeterminate Tuberculosis spot test at screening Any active infection at the time of screening or admission Consumption of any nutrients known to modulate cytochrome P450 enzyme activity within 14 days prior to administration of study drug, during the study, and until after discharge</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Healthy subjects</keyword>
	<keyword>DDI</keyword>
	<keyword>CYP3A</keyword>
</DOC>